These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38265527)

  • 1. Clinically relevant molecular hallmarks of PFA ependymomas display intratumoral heterogeneity and correlate with tumor morphology.
    Gödicke S; Kresbach C; Ehlert M; Obrecht D; Altendorf L; Hack K; von Hoff K; Carén H; Melcher V; Kerl K; Englinger B; Filbin M; Pajtler KW; Gojo J; Pietsch T; Rutkowski S; Schüller U
    Acta Neuropathol; 2024 Jan; 147(1):23. PubMed ID: 38265527
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneity within the PF-EPN-B ependymoma subgroup.
    Cavalli FMG; Hübner JM; Sharma T; Luu B; Sill M; Zapotocky M; Mack SC; Witt H; Lin T; Shih DJH; Ho B; Santi M; Emery L; Hukin J; Dunham C; McLendon RE; Lipp ES; Gururangan S; Grossbach A; French P; Kros JM; van Veelen MC; Rao AAN; Giannini C; Leary S; Jung S; Faria CC; Mora J; Schüller U; Alonso MM; Chan JA; Klekner A; Chambless LB; Hwang EI; Massimino M; Eberhart CG; Karajannis MA; Lu B; Liau LM; Zollo M; Ferrucci V; Carlotti C; Tirapelli DPC; Tabori U; Bouffet E; Ryzhova M; Ellison DW; Merchant TE; Gilbert MR; Armstrong TS; Korshunov A; Pfister SM; Taylor MD; Aldape K; Pajtler KW; Kool M; Ramaswamy V
    Acta Neuropathol; 2018 Aug; 136(2):227-237. PubMed ID: 30019219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q.
    Baroni LV; Sundaresan L; Heled A; Coltin H; Pajtler KW; Lin T; Merchant TE; McLendon R; Faria C; Buntine M; White CL; Pfister SM; Gilbert MR; Armstrong TS; Bouffet E; Kumar S; Taylor MD; Aldape KD; Ellison DW; Gottardo NG; Kool M; Korshunov A; Hansford JR; Ramaswamy V
    Neuro Oncol; 2021 Aug; 23(8):1360-1370. PubMed ID: 33580238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular characteristics and improved survival prediction in a cohort of 2023 ependymomas.
    Pohl LC; Leitheiser M; Obrecht D; Schweizer L; Wefers AK; Eckhardt A; Raffeld M; Sturm D; Pajtler KW; Rutkowski S; Fukuoka K; Ichimura K; Bockmayr M; Schüller U
    Acta Neuropathol; 2024 Jan; 147(1):24. PubMed ID: 38265522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Significant increase of high-risk chromosome 1q gain and 6q loss at recurrence in posterior fossa group A ependymoma: A multicenter study.
    Donson AM; Bertrand KC; Riemondy KA; Gao D; Zhuang Y; Sanford B; Norris GA; Chapman RJ; Fu R; Willard N; Griesinger AM; Ribeiro de Sousa G; Amani V; Grimaldo E; Hankinson TC; Booker F; Sill M; Grundy RG; Pajtler KW; Ellison DW; Foreman NK; Ritzmann TA
    Neuro Oncol; 2023 Oct; 25(10):1854-1867. PubMed ID: 37246777
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chromosome 1q gain and tenascin-C expression are candidate markers to define different risk groups in pediatric posterior fossa ependymoma.
    Araki A; Chocholous M; Gojo J; Dorfer C; Czech T; Heinzl H; Dieckmann K; Ambros IM; Ambros PF; Slavc I; Haberler C
    Acta Neuropathol Commun; 2016 Aug; 4(1):88. PubMed ID: 27550150
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors.
    Fukuoka K; Kanemura Y; Shofuda T; Fukushima S; Yamashita S; Narushima D; Kato M; Honda-Kitahara M; Ichikawa H; Kohno T; Sasaki A; Hirato J; Hirose T; Komori T; Satomi K; Yoshida A; Yamasaki K; Nakano Y; Takada A; Nakamura T; Takami H; Matsushita Y; Suzuki T; Nakamura H; Makino K; Sonoda Y; Saito R; Tominaga T; Matsusaka Y; Kobayashi K; Nagane M; Furuta T; Nakada M; Narita Y; Hirose Y; Ohba S; Wada A; Shimizu K; Kurozumi K; Date I; Fukai J; Miyairi Y; Kagawa N; Kawamura A; Yoshida M; Nishida N; Wataya T; Yamaoka M; Tsuyuguchi N; Uda T; Takahashi M; Nakano Y; Akai T; Izumoto S; Nonaka M; Yoshifuji K; Kodama Y; Mano M; Ozawa T; Ramaswamy V; Taylor MD; Ushijima T; Shibui S; Yamasaki M; Arai H; Sakamoto H; Nishikawa R; Ichimura K;
    Acta Neuropathol Commun; 2018 Dec; 6(1):134. PubMed ID: 30514397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing biomarkers for accurate ependymoma diagnosis, prognostication, and stratification within International Clinical Trials: A BIOMECA study.
    Chapman RJ; Ghasemi DR; Andreiuolo F; Zschernack V; Espariat AT; Buttarelli FR; Giangaspero F; Grill J; Haberler C; Paine SML; Scott I; Jacques TS; Sill M; Pfister S; Kilday JP; Leblond P; Massimino M; Witt H; Modena P; Varlet P; Pietsch T; Grundy RG; Pajtler KW; Ritzmann TA
    Neuro Oncol; 2023 Oct; 25(10):1871-1882. PubMed ID: 36916248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A retrospective analysis of recurrent pediatric ependymoma reveals extremely poor survival and ineffectiveness of current treatments across central nervous system locations and molecular subgroups.
    Ritzmann TA; Rogers HA; Paine SML; Storer LCD; Jacques TS; Chapman RJ; Ellison D; Donson AM; Foreman NK; Grundy RG
    Pediatr Blood Cancer; 2020 Sep; 67(9):e28426. PubMed ID: 32614133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome.
    Panwalkar P; Clark J; Ramaswamy V; Hawes D; Yang F; Dunham C; Yip S; Hukin J; Sun Y; Schipper MJ; Chavez L; Margol A; Pekmezci M; Chung C; Banda A; Bayliss JM; Curry SJ; Santi M; Rodriguez FJ; Snuderl M; Karajannis MA; Saratsis AM; Horbinski CM; Carret AS; Wilson B; Johnston D; Lafay-Cousin L; Zelcer S; Eisenstat D; Silva M; Scheinemann K; Jabado N; McNeely PD; Kool M; Pfister SM; Taylor MD; Hawkins C; Korshunov A; Judkins AR; Venneti S
    Acta Neuropathol; 2017 Nov; 134(5):705-714. PubMed ID: 28733933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcriptomic and epigenetic dissection of spinal ependymoma (SP-EPN) identifies clinically relevant subtypes enriched for tumors with and without NF2 mutation.
    Neyazi S; Yamazawa E; Hack K; Tanaka S; Nagae G; Kresbach C; Umeda T; Eckhardt A; Tatsuno K; Pohl L; Hana T; Bockmayr M; Kim P; Dorostkar MM; Takami T; Obrecht D; Takai K; Suwala AK; Komori T; Godbole S; Wefers AK; Otani R; Neumann JE; Higuchi F; Schweizer L; Nakanishi Y; Monoranu CM; Takami H; Engertsberger L; Yamada K; Ruf V; Nomura M; Mohme T; Mukasa A; Herms J; Takayanagi S; Mynarek M; Matsuura R; Lamszus K; Ishii K; Kluwe L; Imai H; von Deimling A; Koike T; Benesch M; Kushihara Y; Snuderl M; Nambu S; Frank S; Omura T; Hagel C; Kugasawa K; Mautner VF; Ichimura K; Rutkowski S; Aburatani H; Saito N; Schüller U
    Acta Neuropathol; 2024 Jan; 147(1):22. PubMed ID: 38265489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas.
    Pajtler KW; Wen J; Sill M; Lin T; Orisme W; Tang B; Hübner JM; Ramaswamy V; Jia S; Dalton JD; Haupfear K; Rogers HA; Punchihewa C; Lee R; Easton J; Wu G; Ritzmann TA; Chapman R; Chavez L; Boop FA; Klimo P; Sabin ND; Ogg R; Mack SC; Freibaum BD; Kim HJ; Witt H; Jones DTW; Vo B; Gajjar A; Pounds S; Onar-Thomas A; Roussel MF; Zhang J; Taylor JP; Merchant TE; Grundy R; Tatevossian RG; Taylor MD; Pfister SM; Korshunov A; Kool M; Ellison DW
    Acta Neuropathol; 2018 Aug; 136(2):211-226. PubMed ID: 29909548
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain.
    Gojo J; Lötsch D; Spiegl-Kreinecker S; Pajtler KW; Neumayer K; Korbel P; Araki A; Brandstetter A; Mohr T; Hovestadt V; Chavez L; Kirchhofer D; Ricken G; Stefanits H; Korshunov A; Pfister SM; Dieckmann K; Azizi AA; Czech T; Filipits M; Kool M; Peyrl A; Slavc I; Berger W; Haberler C
    Neuro Oncol; 2017 Sep; 19(9):1183-1194. PubMed ID: 28371821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging features to distinguish posterior fossa ependymoma subgroups.
    Leclerc T; Levy R; Tauziède-Espariat A; Roux CJ; Beccaria K; Blauwblomme T; Puget S; Grill J; Dufour C; Guerrini-Rousseau L; Abbou S; Bolle S; Roux A; Pallud J; Provost C; Oppenheim C; Varlet P; Boddaert N; Dangouloff-Ros V
    Eur Radiol; 2024 Mar; 34(3):1534-1544. PubMed ID: 37658900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Posterior fossa ependymoma H3 K27-mutant: an integrated radiological and histomolecular tumor analysis.
    Mariet C; Castel D; Grill J; Saffroy R; Dangouloff-Ros V; Boddaert N; Llamas-Guttierrez F; Chappé C; Puget S; Hasty L; Chrétien F; Métais A; Varlet P; Tauziède-Espariat A
    Acta Neuropathol Commun; 2022 Sep; 10(1):137. PubMed ID: 36104744
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of chromosome 1q gain in intracranial ependymomas.
    Rajeshwari M; Sharma MC; Kakkar A; Nambirajan A; Suri V; Sarkar C; Singh M; Saran RK; Gupta RK
    J Neurooncol; 2016 Apr; 127(2):271-8. PubMed ID: 26725097
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Whitehouse JP; Hii H; Mayoh C; Wong M; Ajuyah P; Barahona P; Cui L; Dholaria H; White CL; Buntine MK; Byrne J; Rodrigues da Silva K; Howlett M; Girard EJ; Tsoli M; Ziegler DS; Dyke JM; Lee S; Ekert PG; Cowley MJ; Gottardo NG; Endersby R
    Front Oncol; 2023; 13():1123492. PubMed ID: 36937401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of key methylation differentially expressed genes in posterior fossa ependymoma based on epigenomic and transcriptome analysis.
    Wang G; Jia Y; Ye Y; Kang E; Chen H; Wang J; He X
    J Transl Med; 2021 Apr; 19(1):174. PubMed ID: 33902636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular characterization of histopathological ependymoma variants.
    Neumann JE; Spohn M; Obrecht D; Mynarek M; Thomas C; Hasselblatt M; Dorostkar MM; Wefers AK; Frank S; Monoranu CM; Koch A; Witt H; Kool M; Pajtler KW; Rutkowski S; Glatzel M; Schüller U
    Acta Neuropathol; 2020 Feb; 139(2):305-318. PubMed ID: 31679042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adult intracranial ependymoma-relevance of DNA methylation profiling for diagnosis, prognosis, and treatment.
    Träger M; Schweizer L; Pérez E; Schmid S; Hain EG; Dittmayer C; Onken J; Fukuoka K; Ichimura K; Schüller U; Dührsen L; Müther M; Paulus W; Thomas C; Gutt-Will M; Schucht P; Maragkou T; Schittenhelm J; Eckert F; Niyazi M; Fleischmann DF; Dorostkar MM; Feyer P; May SA; Moskopp D; Badakhshi H; Radke C; Walter J; Ehret F; Capper D; Kaul D
    Neuro Oncol; 2023 Jul; 25(7):1286-1298. PubMed ID: 36734226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.